Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· December 6, 2025

Is It Better to Collect Social Security at 62, 67, or 70? A Broad-Based Statistical Analysis Provides a Decisive Answer.

View original at nasdaq.com
Is It Better to Collect Social Security at 62, 67, or 70? A Broad-Based Statistical Analysis Provides a Decisive Answer. Key Points The Social Security Administration uses four straightforward variables to calculate your monthly Social Security benefit…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • One easy trick could pay you as much as $23,760 more each year in Social Security benefits

    80% confidence
  • Retired workers could see their payouts reduced by up to 23% in 2033

    80% confidence
  • 80% to 90% of Social Security beneficiaries need their payout in some capacity to make ends meet

    80% confidence
  • 57% of the 20,000 claims studied would have been optimal at age 70

    80% confidence
  • Around 10% of claims at age 67 would have been optimal

    80% confidence
  • Only 4% of the 20,000 retired-worker claims analyzed were optimal

    80% confidence
  • 79% of the 20,000 retired-worker claims examined had an initial collection age ranging from 62 through 64, but only 8% of optimal claims occurred at these three claiming ages combined

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com